Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.

Seung Tae KimSimon A SmithPeter G S MortimerArsene-Bienvenu LoembéHeejin ChoKyoung-Mee KimClaire SmithSophie WillisItziar Irurzun-AranaAlienor BergesJung Yong HongSe Hoon ParkJoon Oh ParkYoung Suk ParkHo Yeong LimWon Ki KangIwanka KozarewaAndrew J PierceEmma DeanJeeyun Lee

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Ceralasertib in combination with paclitaxel was well tolerated in patients with advanced malignancies and showed evidence of antitumor activity. Durable responses were observed in patients with advanced cutaneous, acral, and mucosal melanoma resistant to anti-PD1/L1 treatment.See related commentary by Ashworth, p. 4667.

Keyphrases

dna damage
papillary thyroid
oxidative stress
squamous cell
skin cancer
young adults
smoking cessation
drug induced
replacement therapy